Application of Immune Checkpoint Inhibitors in EGFR Mutant 
Advanced Non-small Cell Lung Cancer

Application of Immune Checkpoint Inhibitors in EGFR Mutant 
Advanced Non-small Cell Lung Cancer

In recent years, immune checkpoint inhibitors (ICIs) have greatly improved the survival rate of non-small cell lung cancer (NSCLC) patients without driver mutation. Compared with wild-type tumors, tumors with epidermal growth factor receptor (EGFR) mutations have greater heterogeneity in immune micr...

Full description

Bibliographic Details
Main Authors: Yujun ZHENG, Wei JIANG, Jing LI, Lulu DAI, Dongyan CHEN, Yanjun LI, Lei HUANG, Mingji WANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2022-09-01
Series:Chinese Journal of Lung Cancer
Subjects:
molecular characteristics
inmune checkpoint inhibitors
lung neoplasms
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.32

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.32

Similar Items